Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Tumour heterogeneity and the impact on patient care

Share :

Future Horizons in Lung Cancer

1 - 2 Sep 2016
Sorry, this item is currently unavailable.
Published: 5 Oct 2016
Views: 2128
Rating:
Save
Dr Nicholas McGranahan - The Francis Crick Institute, London, UK

Dr McGranahan presents at the Future Horizons in Lung Cancer meeting about tumour heterogeneity and the impact on patient care.

 

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Lung Cancer

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India
Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )
6 Nov 2023

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart
Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )
2 Nov 2023

A reproducibility study in pulmonary adenocarcinomas supports a revised classification

Dr Erik Thunnissen - VU University Medical Center, Amsterdam, The Netherlands
A reproducibility study in pulmonary adenocarcinomas supports a revised classification ( Dr Erik Thunnissen - VU University Medical Center, Amsterdam, The Netherlands )
12 Sep 2023

ASCO 2023: Lung cancer research highlights

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
ASCO 2023: Lung cancer research highlights ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
26 Jun 2023

Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma

Prof Peter Szlosarek - Barts Cancer Institute, London, UK
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma ( Prof Peter Szlosarek - Barts Cancer Institute, London, UK )
26 Apr 2023

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
11 Apr 2023

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation